跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/CTRI/2017/12/010788
CTRI/2017/12/010788已完成1 期

Phase 1 clinical trial for assessment of safety of a multi component botanical therapeutic (SKBDEVI) in healthy human volunteers

SK Biolabs1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 1999年1月2日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
100
试验地点
1
主要终点
Any toxic side effects after oral intake of SKBDEVI such as fever, nausea, vomiting, headache, depression, irritation, anxiety, palpitation, choking, fainting, cough, skin rashes etc.
研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

Multi component botanical therapeutic SKBDEVI causes no toxicity in healthy human volunteers except some volunteers reported mild constipation after 4 weeks.

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Not Applicable

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)（—）
性别
All

入选标准

  • •Healthy Human Volunteers.

排除标准

  • •Patients suffering from any disease.

结局指标

主要结局

Any toxic side effects after oral intake of SKBDEVI such as fever, nausea, vomiting, headache, depression, irritation, anxiety, palpitation, choking, fainting, cough, skin rashes etc.

时间窗: 1 day

次要结局

  • Any toxic side effects after oral intake of SKBDEVI such as fever, nausea, vomiting, headache, depression, irritation, anxiety, palpitation, choking, fainting, cough, skin rashes etc.(4 weeks)

研究者

发起方
SK Biolabs
申办方类型
Research institution

研究点 (1)

Loading locations...

相似试验

进行中（未招募）
1 期
A study of JNJ-88549968 for the treatment of calreticulin (CALR)-mutated myeloproliferative neoplasmsCalreticulin (CALR)-mutated myeloproliferative neoplasmsCancer
ISRCTN79300015Janssen Research & Development, LLC100
进行中（未招募）
1 期
A Phase I/II clinical study to investigate the safety and effectiveness of BT8009 in patients with advanced malignanciesectin-4 Expressing Advanced Malignancies.
EUCTR2020-002719-23-ITBicycleTx Limited146
进行中（未招募）
1 期
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients with Advanced Malignancies Associated with EphA2 Expressio
EUCTR2019-003653-29-ESBicycle Tx Limited166
进行中（未招募）
1 期
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients with Advanced Malignancies Associated with EphA2 ExpressioAdvanced Malignancies Associated with EphA2 ExpressionMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864
EUCTR2019-003653-29-GBBicycle Tx Limited166
进行中（未招募）
1 期
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients with Advanced Malignancies Associated with EphA2 ExpressioAdvanced Malignancies Associated with EphA2 ExpressionMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864
EUCTR2019-003653-29-BEBicycleTx Limited288